# EDGAR Filing Document

**Accession Number:** 0000313143
**File Stem:** 0000313143-26-000057
**Filing Date:** 2026-6
**Character Count:** 12933
**Document Hash:** 8a938a1c58e22fe9a9e46a4bd48324e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000313143-26-000057.hdr.sgml**: 20260605

**ACCESSION NUMBER**: 0000313143-26-000057

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260605

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260605

**DATE AS OF CHANGE**: 20260605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HAEMONETICS CORP
- **CENTRAL INDEX KEY:** 0000313143
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 042882273
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 0328

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14041
- **FILM NUMBER:** 261066817

**BUSINESS ADDRESS:**
- **STREET 1:** 125 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 7818487100

**MAIL ADDRESS:**
- **STREET 1:** 125 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version='1.0' encoding='ASCII'? hae-20260605

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 5, 2026** 

**HAEMONETICS CORPORATION** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Massachusetts** | **001-14041** | **04-2882273** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

---

**125 Summer Street**

**Boston, MA 02110** 

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **781-848-7100** 

(Former name or former address, if changed since last report.)

---

| | |
|:---|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $.01 par value per share | HAE | New York Stock Exchange |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging Growth Company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

------

**Item 7.01 Regulation FD Disclosure.**

On June 5, 2026, Haemonetics Corporation (the "Company") issued a press release announcing changes to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Beginning with the first quarter of fiscal 2027, the previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying businesses, technologies, and markets served. In connection with this announcement, the Company has posted to the Investor Relations page on its website (www.haemonetics.com) a supplemental presentation outlining the reporting changes, including quarterly historical reconciliations from the first quarter of fiscal year 2024 through the fourth quarter of fiscal year 2026, and the company has provided a recast of its previously issued fiscal 2027 guidance in the new segment structure. The Company is not reaffirming or updating its previously issued fiscal year 2027 guidance. Updates, if any, will be provided on the Company's first quarter fiscal year 2027 earnings call.

The foregoing information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d)&nbsp;&nbsp;&nbsp;&nbsp;**Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| <u>[99.1](ex991-pressrelease652026.htm)</u> | Press Release issued by Haemonetics Corporation on June 5, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **HAEMONETICS CORPORATION** | **HAEMONETICS CORPORATION** |
| June 5, 2026 | By: | /s/ Christopher A. Simon |
|  | Name: | Christopher A. Simon |
|  | Title: | President and Chief Executive Officer |

---

## Exhibit 99.1

![newlogoa.jpg](newlogoa.jpg)

**Exhibit 99.1**

---

| | |
|:---|:---|
| **Investor Contacts** | **Media Contact** |
| Olga Guyette, Vice President - Investor Relations & Treasury<br>(781) 356-9763 <br><u>olga.guyette@haemonetics.com</u>  | Josh Gitelson, Sr. Director - Global Communications<br>(781) 356-9776<br><u>josh.gitelson@haemonetics.com</u> |
| David Trenk, Sr. Manager - Investor Relations<br>(203) 733-4987<br><u>david.trenk@haemonetics.com</u>  |  |

---

**Haemonetics Updates Financial Reporting Segments**

**BOSTON, MA, June 5, 2026** — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two. The previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying businesses, technologies, and markets served.

Consistent with prior practice, Haemonetics expects to continue providing additional supplemental revenue disclosure in its earnings materials. The Apheresis segment will include supplemental disclosure for Plasma and Other, while the MedSurg segment will continue to include Blood Management Technologies and Interventional Technologies.

Haemonetics will begin reporting financial results under its new reportable segment structure with the first quarter of fiscal year 2027, which commenced on March 29, 2026. To facilitate comparability, the Company has posted a supplemental presentation containing recast quarterly historical revenue for fiscal years 2024, 2025, and 2026, as well as a recast of its previously issued fiscal year 2027 revenue guidance to align historical and guidance disclosures with the new reportable segment structure. The supplemental presentation is not a reaffirmation or update of the Company's previously issued fiscal year 2027 guidance. Updates, if any, will be provided on the Company's first quarter fiscal year 2027 earnings call.

The supplemental presentation is available on the Company's Investor Relations website which may be accessed at <u>https://haemonetics.gcs-web.com/static-files/329078b2-08fa-45a4-ba29-f069a3e18ec3</u>.

**<u>About Haemonetics</u>**

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit <u>www.haemonetics.com</u>.

------

**FORWARD-LOOKING STATEMENTS**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) the change in the Company's reportable segments, and prospective supplemental disclosures within this framework; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company's products; the Company's ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company's ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company's ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program's effectiveness. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the "SEC"). The Company does not undertake to update these forward-looking statements.

<br>